The secret to treating sepsis has been revealed?
Griffith University researchers may have unlocked the secret to treating sepsis, with a Phase II clinical trial in China successfully concluding with promising results.
Press release from Griffith University:
Griffith University researchers may have unlocked the secret to treating sepsis, with a Phase II clinical trial in China successfully concluding with promising results.
The sepsis drug candidate, a carbohydrate-based drug called STC3141, was co-developed by Distinguished Professor Mark von Itzstein AO FAA FAHMS FRACI AO and his team from Griffith University Institute for Biomedicine and Glycomics, and Professor Christopher Parish and his team at The Australian National University.
“The trial met the key endpoints to indicate the drug candidate was successful in reducing sepsis in humans,” Professor von Itzstein said.
The small-molecule experimental drug was a carbohydrate-based molecule and could treat sepsis by reversing organ damage.
“When sepsis is not recognised early and managed promptly, it can lead to septic shock, multiple organ failure and death,” Distinguished Professor von Itzstein said.
The trial, conducted by Grand Pharmaceutical Group Limited (Grand Pharma), involved 180 patients with sepsis, one of the leading causes of death and long-term disability worldwide.
Currently, there is no specific anti-sepsis therapy available, and sepsis is considered a clinical unmet need.
Professor von Itzstein said Grand Pharma would now look to progress to a Phase III trial to continue testing the efficacy of the novel treatment.
“It’s hoped we could see the treatment reach the market in a handful years, potentially saving millions of lives,” he said.
Griffith University:
Australian National University:
Professor Mark von Itzstein:
experts.griffith.edu.au/18853-mark-von-itzstein
Professor Mark von Itzstein AO was the founding Director of Griffith University’s Institute for Glycomics in 2000. He has a major research effort in the area of drug discovery, with a carbohydrate-based drug candidate against sepsis in phase 2 human clinical trials. Professor von Itzstein led the team responsible for the design, synthesis and biological evaluation of the anti-influenza drug, Relenza®, which has been approved for the treatment of influenza worldwide since 1999. This discovery is considered to be a significant outcome and flagship in glycotherapeutic and antiviral drug development in the last century.
Photo: © Griffith University
All rights belong to: (for this news)
Griffith University - Griffith University Institute for Biomedicine and Glycomics
Australian National University
Professor Mark von Itzstein AO FAA FAHMS FRACI AO
Projekt owner & Team on Projekt
